尼可占替诺与川芎嗪治疗脑血管疾病后慢性脑功能障碍比较

Xantinol nicotinate vs ligustrazine in treating chronic cerebral functional disorder after cerebral blood vessel disease

目的：比较尼可占替诺与川芎嗪治疗脑血管疾病后慢性脑功能障碍的疗效。方法：６４例脑血管疾病后慢性脑功能障碍病人随机分为２组，３２例为治疗组，予尼可占替诺０．３～０．９ｇ；另３２例为对照组，予川芎嗪１６０ｍｇ，分别加入５％葡萄糖或０．９％氯化钠注射液５００ｍＬ中，ｉｖ，ｄｒｉｐ，２组均以２０ｄ为一个疗程。结果：治疗组与对照组的精神症状、神经体征和智能障碍总有效率分别为９４％和７５％（Ｐ＜０．０５），９１％和８１％（Ｐ＞０．０５），８１％和５６％（Ｐ＜０．０５）。尼可占替诺不良反应少。

AIM: To compare xantinol nicotinate and ligustrazine in treating chronic cerebral functional disorder after cerebral blood vessel diseases. METHODS: Sixty_four patients were randomly divided into 2 groups: 32 patients (M 18, F 14; age 62 a s 7 a) were treated with xantinol nicotinate 0.3_0.9 g, another 32 patients (M 17, F 15, age 65 a8 a) were treated with ligustrazine 160 mg. These drugs were added in 5% glucose injection or 0.9% sodium chloride injection 500 mL, iv drip, qd for 20 d. RESULTS: The general effective rates of mental symptoms, nervous signs and intelligence disorder in 2 groups were 94% vs 75% ( P <0.05), 91% vs 81%(TBX]P >0.05), 81% vs 56%( P <0.05). Adverse reactions were rare. CONCLUSION: Xantinol nicotinate improves the mental symptoms and intelligence disorder in patients with chronic cerebral functional disorder after cerebral blood vessel diseases more effectively than ligustrazine.